Publication details

miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities

Authors

MRÁZ Marek MALINOVÁ Karla KOTAŠKOVÁ Jana PAVLOVÁ Šárka TICHÝ Boris MALČÍKOVÁ Jitka STAŇO KOZUBÍK Kateřina ŠMARDOVÁ Jana BRYCHTOVÁ Yvona DOUBEK Michael TRBUŠEK Martin MAYER Jiří POSPÍŠILOVÁ Šárka

Year of publication 2009
Type Article in Periodical
Magazine / Source Leukemia
MU Faculty or unit

Faculty of Medicine

Citation
Doi http://dx.doi.org/10.1038/leu.2008.377
Field Oncology and hematology
Keywords CHRONIC LYMPHOCYTIC-LEUKEMIA; EXPRESSION; MICRORNAS
Description Chronic lymphocytic leukemia (CLL) is the most common leukemia in the western world and is characterized by a highly variable clinical course. CLL can be classified into two biological subtypes, according to the presence or absence of somatic mutations in the immunoglobulin heavy-chain variable region (IgVH). IgVH mutational status is of high-clinical relevance: cases with unmutated IgVH show a less favorable course with a rapid progression, whereas cases with mutated IgVH show a stable disease and longer survival. Unfavorable prognosis is also associated with the inactivation of an important tumor-suppressor p53; these patients harbor a deletion of 17p13 and this chromosomal abnormality is often accompanied by the mutation of the second TP53 allele, which leads to the complete elimination of p53 function. Moreover, a single mutation of one of the TP53 allele also occurs in a significant proportion of CLL cases. Patients with TP53 abnormalities typically do not respond to therapy and have a median survival of less than 3 years.

You are running an old browser version. We recommend updating your browser to its latest version.

More info